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ABSTRACT 
 
Objectives, setting and patients: With complete case referral for prolonged 
parenteral nutrition (PN) beyond term equivalent, serving a stable population of 1.25 
million people, we describe the long term outcome and survival of patients referred to 
an intestinal failure (IF) nutrition support team over the first eight years of existence 
at a regional paediatric centre, and extrapolate to potential numbers of national home 
parenteral nutrition (HPN) cases and intestinal transplantation data.  
 
Design and outcome measures: Retrospective analysis detailing patient 
demographics, interventions, use of home parenteral nutrition (HPN), occurrence of 
intestinal failure associated liver disease (IFALD), and outcomes of enteral 
adaptation, survival, and referral for and receipt of organ transplantation. 
 
Results: 23 patients were referred over eight years, 20 being PN dependent within the 
neonatal period. Diagnoses included short bowel syndrome (SBS) (18), 
neuromuscular abnormalities (4) and congenital enterocyte disorder (1).  12,696 days 
of PN were delivered with 314 confirmed episodes of sepsis at a median of twelve 
episodes per patient. 144 central venous catheters (CVC) were required at a median of 
four per patient. IFALD occurred in seventeen (73%) patients, with ten (44%) referred 
for transplant assessment. Thirteen (56%) children received HPN.  Overall mortality 
was 44%. A significant predictor for survival in the SBS group was residual bowel 
>40cm (82% vs. 28%, p=0.049). 
 
Conclusions:  Survival for IF at 56% was lower than reported from non UK supra-
regional centres, and nationally collected data, possibly reflecting pre-selected referral 
populations. Data from regional centres with complete ascertainment may be 
important both when counselling parents and when planning regional and national 
HPN and IF specialist services.  
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Abbreviations 
 
IF- intestinal failure, PN- parenteral nutrition, IFALD- intestinal failure associated 
liver disease, SBS –short bowel syndrome, NEC- necrotising enterocolitis, CIPOS- 
congenital intestinal pseudo-obstruction syndrome, RHSC- Royal Hospital for Sick 
Children Edinburgh, CSBLT- combined small bowel liver transplant, HPN- home 
parenteral nutrition, ICV- ileocaecal valve, CVC- central venous catheter, ILT- 
isolated liver transplant, NST- nutrition support team NST. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                
 
OBJECTIVES 
Intestinal failure (IF) is defined as the reduction of functional gastrointestinal mass 
below that needed for digestion and absorption of fluid and nutrients for maintenance 
in adults and growth in children (1-3), and can be separated into three main groups by 
pathogenesis (4;5). 1. Short bowel syndrome (SBS) (6). 2. Neuromuscular disorders 
of the gastrointestinal tract including; Long segment aganglionosis (Hirschsprung’s 
Disease) and congenital intestinal pseudo-obstruction syndromes (CIPOS)(7). 3. 
Congenital enterocyte disorders (8;9). Parenteral nutrition (PN) has dramatically 
improved the previously dismal prognosis for this patient population (1;5;10). 
However, significant complications of management, such as central line sepsis, 
intestinal failure associated liver disease (IFALD) and growth failure, have 
contributed to long-term morbidity and mortality in IF (1;5;11). Combined small 
bowel and liver transplantation (CSBLT) now offers alternative treatment for patients 
surviving with irreversible IF (5;12). Currently care for IF in the UK is performed in 
regional paediatric gastroenterology and nutrition services with multidisciplinary 
nutrition support teams (NST). (13) There is a single intestinal transplantation unit 
located at Birmingham Children’s Hospital. Outwith the U.K., national centres of 
excellence for management of long-term IF and HPN exist (14). Outcomes for 
patients with longstanding IF appear to be improving from data both collected from 
national centres of excellence (outwith the U.K.) and from intestinal transplantation 
services (14;15). However there is a paucity of incidence and outcome data for such 
patients from regional centres. This study aimed to describe the incidence, prevalence 
and long-term outcome of IF  referred to a regional nutrition support team (NST), 
when all cases from a geographical region are obtained, and to extrapolate these data 
for potential use of national HPN and intestinal transplant services. 
 
 
METHODS 
SETTING AND PATIENTS 
Following the appointment of a consultant in paediatric gastroenterology and nutrition 
in August 1997, the Royal Hospital for Sick Children, Edinburgh (RHSC) developed 
a multidisciplinary IF NST. This consisted of a consultant paediatric 
gastroenterologist, consultant paediatric surgeons, specialist paediatric nutrition nurse, 
paediatric dieticians, specialist paediatric pharmacist, ward nursing staff, and 
specialist social worker. RHSC serves as the single tertiary paediatric unit to the 
region of SE Scotland with a stable population of around 1.25 million and provides all 
PN to post-term infants and children. Referral to the team is made from within RHSC 
(Medical or Surgical teams), from four other district general paediatric units, two 
level three NICU and two level two neonatal nurseries within the region. The aims of 
the team were to optimise the long term outcome of patients identified as having IF by 
maximising enteral nutrition, facilitating the use of parenteral nutrition at home 
(HPN) and acting as a point of referral to UK national transplantation services when 
required. 
 
In-patients are managed in a combined medical and surgical ward and are reviewed 
by the multidisciplinary ward-round on a daily basis with alterations to therapies and 
PN being made to optimise bowel adaptation. PN prescription is done in conjunction 
with a senior specialist paediatric pharmacist. Central lines are placed and removed by 
paediatric surgeons dedicated to the NST. Training and supervision of line-care by 
ward staff, junior doctors and parents is coordinated by a dedicated nutrition nurse 
                                                
 
specialist. PN is always cycled to an optimal level dependent upon age, prematurity 
and clinical status. Enteral feeding is modified by the NST specialist paediatric 
dietician. As a rule, when available, mother’s milk is the first feed. When not tolerated 
a semi elemental feed is normally trialled followed, if necessary, by completely 
elemental diet. Feeds high in MCT are given when patient is significantly cholestatic. 
Modular feeds are reserved for patients with specific indications, such as suggestion 
of very low threshold of carbohydrate tolerance. Bilirubin, liver enzymes and 
synthetic function are assessed weekly with micronutrient nutritional screening on a 
monthly basis. When IFALD is identified management involves a protocol of 
investigation for other causes of cholestatic liver disease, a review of enteral and 
parenteral nutrition and commencement of ursodeoxycholic acid. A standard sepsis 
protocol of broad spectrum antibiotics for fever above 38.50C or recurrent fever above 
38.00C exists. Individual patient sepsis protocols are established in conjunction with a 
specialist consultant microbiologist and are available on the front of patient’s case 
notes. The specialist nutrition nurse trains parents to handle PN and the dedicated 
social worker identifies and rectifies non-medical hindrances to discharge. HPN 
patients are discussed in a multidisciplinary meeting weekly, with emphasis being 
placed on optimising enteral nutrition, sepsis prevention and management and quality 
of life issues. Patients are seen in a dedicated IF clinic after discharge. We work 
within the Scottish HPN managed clinical network (www.shpnmcn.scot.nhs.uk) 
which aims to facilitate excellence and standardisation of care for all HPN patients 
across Scotland. 
 
DESIGN AND OUTCOME MEASURES 
Data were obtained retrospectively from the medical records of patients from the IF 
NST database, logged prospectively from August 1997 to June 2005. These data were 
analysed by database Excel for Windows (Microsoft Office XP).  Entry criteria were 
patients referred to the regional paediatric NST with a primary gastrointestinal 
disorder, and whom must have received > 28days PN by completion of study. 
Demographic data obtained for patients at point of referral to the team were date of 
birth, age at referral, birth weight, gestational age at birth, diagnoses, weight at 
referral and number of days of PN at referral. Patients were grouped according to 
cause of IF - SBS, neuromuscular disease or enterocyte disorder. 
 
SBS patients had additional data recorded for primary diagnosis. Initial surgical 
records were reviewed and residual small bowel length recorded. Where only length 
of bowel resected was recorded, an estimated residual bowel length was calculated 
using a standardised formula against gestation (16).   Other surgical details recorded 
were; primary anastomoses, defunctioning stomas, and whether the ileo-caecal (ICV) 
valve had been removed. Patients with neuromuscular disease had primary diagnosis 
and subsequent surgical procedures noted. Longitudinal data were then obtained to 
evaluate patient management and outcomes in the following categories: 
 
1. PN and enteral adaptation; Recorded items were the total number of days of PN, 
total number of semi-permanent tunnelled central venous catheters (CVC) required 
and other complications of PN (line occlusion, thrombosis, growth failure, pubertal 
delay, IFALD), proportion of patients who received HPN, and the number of 
confirmed episodes of bacterial/fungal sepsis (defined as clinical signs of sepsis in 
combination with a significant growth of appropriate organism from CVC culture, 
peripheral line culture or peripheral venous culture, with resolution of symptoms with 
                                                
 
appropriate antibiotic therapy). Further cultures of the same organism were not 
considered to be a separate septic episode until patient had remained afebrile for five 
days off antibiotic treatment. We defined enteral adaptation as <10% weight loss after 
cessation of PN followed by sustained weight gain. Time to adaptation was recorded 
in months and enteral feed regimen at time of adaptation was also recorded. 
 
2. IFALD, transplantation and outcome; Patients were defined as having IFALD 
(direct bilirubin >50µmol/l) (17) or severely cholestatic (direct bilirubin >100µmol/l) 
either at referral or during their course of treatment. Criteria for referral to the 
intestinal transplantation unit were conjugated Bilirubin > 150μmol/l outwith septic 
episodes, or progressive fibrotic liver disease on biopsy, lack of vascular access, poor 
long-term prognosis or very impaired quality of life for parents/carers or patient. We 
noted whether patients required refrerral for assessment for CBSLT or ILT and if they 
received this assessment, we also noted whether patients were then listed for 
transplantation, and if so, whether they received transplantation. All transplantation 
and transplant assessment was performed at the UK supra-regional Intestinal 
Transplant Assessment Centre at Birmingham Children’s Hospital, Birmingham, UK.  
Outcome data recorded included patient survival, death, age at death, cause of death 
and death whilst awaiting organ transplantation.  
 
3. Extrapolation of regional results to national situation; To determine how our 
data would translate into national statistics, we calculated our service population to be 
2.1% of the UK (1.25/60million x 100%). We then extrapolated what annual 
registration of HPN patient, annual referral to the intestinal transplantation unit, 
CSBLT and ILT would be based on these figures ((n x 100/2.1)/ 8 years). We 
compared our figures with current published UK data on paediatric HPN registration 
(18) and referral to the intestinal transplantation unit (15). 
 
Normally distributed continuous data are described as mean (Standard Deviation), 
non-normally distributed continuous data are described as median (range), and 
categorical data described as number (%).   All statistical analyses were performed 
using Minitab version 14 (Microsoft office XP) and a p value of ≤ 0.05 was 
considered significant. Ethical approval is not required for this type of study, 
confirmed by correspondence with our Local Research Ethics Committee.  
 
RESULTS 
Twenty-three patients were referred to the team (18 SBS, 4 neuromuscular disorders, 
1 epithelial disorder). Patients referred had a median gestation of 35wk (range 25-38 
wk), birthweight of 2.44kg (range 0.65-3.55kg), and were referred at a median age of 
two months (7 days-81 months) having received 35 days PN (0-370 days) 
respectively. (Patient histories are available as a supplemental file). Some variability 
existed in time to referral as a small proportion of patients were already established on 
PN before the creation of the NST. Patient demographics are summarised in table 1. 
Out of the SBS cohort, seven (39%) had residual bowel length less than 40cm, with 
eight (44%) having had their ICV removed.  
 
 
 
 
 
                                                
 
Patient  Diagnosis Gestation 
(weeks) 
Birth 
weight (kg) 
Age  referral 
(Months) 
No of Days 
PN 
Cholestatic 
Patient 1 SBS ( NEC) 28 0.65 1 36 no 
Patient 2 SBS  (gastroschisis) 36 2.75 3 75 yes 
Patient 3 SBS ( NEC)  31 1.38 1 35 yes 
Patient 4 SBS (NEC) 38 2.3 13 370 yes 
Patient 5 SBS (NEC) 32 1.73 21 210 no 
Patient 6 Long segment 
Hirschprungs 
39 2.78 16 0 no 
Patient 7 SBS (NEC) 30 1500 4 14 no 
Patient 8 Congenital 
enterocyte disorder 
40 3.98 <1 0 no 
Patient 9 Long segment 
Hirschprungs 
38 3.91 3 0 no 
Patient 10 SBS (NEC) 33 2.1 2 45 yes 
Patient 11 SBS                  
(SMA thrombosis) 
37 3.0 6 0 no 
Patient 12 CIPOS 39 3.21 81 0 no 
Patient 13 SBS (NEC)  25 0.86 3 90 yes 
Patient 14 SBS (ileal atresia) 35 2.68 <1 21 no 
Patient 15 SBS ( gastroschisis) 36 2.44 <1 3 no 
Patient 16 SBS (NEC) 25 0.85 3 55 yes 
Patient 17 SBS (NEC) 29 1.7 2 46 yes 
Patient 18 CIPOS 36 4.1 2 50 yes 
Patient 19 SBS (ileo-jejunal 
atresia)  
36 3.55 2 21 no 
Patient 20 SBS (NEC) 30 1.68 4 45 no 
Patient 21 SBS ( ileal atresia) 35 2.8 <1 0 No 
Patient 22 SBS (meconium 
ileus) 
39 2.8 <1 12 no 
Patient 23 SBS (NEC) 29 1.18 1 43 yes 
 
Table 1: Demographic data of 23 IF patients referred over eight years 
Cholestasis was defined as serum bilirubin >30 umol/L. Patients were referred before 
commencing PN (i.e. were commenced on PN by the NST). 
 
1. PN, Sepsis, HPN and adaptation 12,696 patient days of PN were delivered at a 
median of 310 days per patient (range 58-2730 days). Thirteen (56%) patients 
received HPN. There were no significant differences in demographic details between 
these patients and those in whom adaptation occurred prior to discharge from hospital.   
There were 314 confirmed episodes of bacterial sepsis (median of twelve episodes per 
patient (2-52)) at a mean of one septic episode per 40.4 patient days. Bacterial and 
fungal growths identified in blood culture are summarised in table 2.  
 
 
 
 
 
 
 
 
 
 
 
                                                
 
 
 
 
 
 
 
 
 
 
 
Table 2: 314 Positive cultures from Central Lines from 23 IF patients receiving 
PN 
 
A total of 144 CVC were placed (median four per patient (range 1-24)). 13/23 patients 
received HPN.  Patients who achieved HPN had a significantly lower infection rate in 
comparison to those who received all PN in the hospital (1 infection per 45.1 PNdays 
vs. 1 per 30.2 PNdays p=0.023, 95%CI -27.6,-2.3). CVC lasted a mean of 80.6 patient 
days, and only five CVC (3%) were removed because of total line occlusion.  We 
identified three major thrombotic complications (one right internal jugular 
thrombosis, one bilateral iliac and one vena cava right atrial). No patients were 
referred for transplant assessment because of loss of vascular access. Only ten (44%) 
patients achieved full enteral adaptation, two of these being post CSBLT and one post 
ILT. Adaptation was achieved at a median of 31 months (range 9-47 months).  
 
2. IFALD, organ transplant and outcome Nine (39%) patients had IFALD at 
referral with six (27%) having severe cholestasis.  Of the SBS cohort, eight (44%) 
cases had already developed IFALD at time of referral with six (33%) being severely 
cholestatic. Seventeen (73%) patients developed cholestasis during the study. Early 
age of referral to the NST (<3/12) and frequent episodes of infection (<30 days) 
positively correlated with subsequent IFALD development (table 3).  
 
Comparator IFALD development (%) Significance  
NEC vs. Non NEC 7/11 (64%) vs. 9/12 (75%) p=0.667 
Age <3/12 vs. >3/12 at 
referral 
11/11 (100%) vs. 5/12 (42%) p=0.005 
Infection rate <30 days vs. 
>30 days 
9/9 (100%) vs. 8/15 (53%) p=0.022 
Preterm vs. Non preterm 13/15 (86%) vs. 5/8 (62.5%) p=0.297 
 
Table 3: IFALD development according to patient characteristics 
 
 
Twelve (52%) patients developed cholestasis reaching levels which indicated need for 
referral to the intestinal transplantation unit in Birmingham for assessment (total 
bilirubin consistently >150μmol/l out-with septic episodes). Ten were assessed; one 
family declined assessment and another patient died whilst awaiting assessment. Five 
(22%) patients have received transplants (four CSBLT, one ILT) and two patients 
died whilst awaiting transplantation. Three remained on the transplant list at the close 
of audit.  In total ten (44%) patients died. Causes of death included end stage liver 
disease (4), sepsis (2), gastrointestinal haemorrhage, post-transplant multi-organ 
 Positive Cultures % 
Coagulase Negative Staphylococcus 145 43 
Enterococcus Faecalis 43 12 
Klebsiella 36 11 
Enterobacter Cloaccae 35 11 
E. Coli 18 5 
Candida  15 4 
Staphylococcus Aureus 12 3 
Streptococcus 11 3 
Pseudomonas 10 3 
Other 11 3 
                                                
 
failure, renal failure and CMV encephalopathy post-transplant. Median age of death 
was 12 months (range 7-107).  Significant predictors for survival in the SBS group 
were residual bowel length >40cm (82% vs. 28%, p=0.049), >3 months age at referral 
to NST (81% vs. 33%, p=0.036) and proceeding to HPN (77% vs. 30%, p=0.04) 
(table 4). 
 
Comparator Survival (%) Significance 
NEC vs. Non NEC 8/11 (73%) vs.  4/12 (34%) p=1.000 
Age <3/12 vs. >3/12 at referral 4/12 (33%) vs. 9/11 (81%) p=0.036 
Preterm vs. Non Preterm 9/15 (60%) vs.4/8 (50%) p=0.685 
HPN vs. Non HPN  10/13 (77%) vs. 3/10 (30%) p=0.040 
Cholestatic vs. Non Cholestatic at 
referral 
8/14 (57%) vs. 5/9 (55%) p=1.000 
Residual bowel length >40cm vs. 
<40cm 
 9/11 (82%) vs. 2/728% p=0.049 
ICV intact vs. ICV removal 6/10 (60%) vs. 5/8 62.5% p=1.000 
Infection rate <30 days vs. >30days 2/9 (22%) vs. 10/15 (66%) p=0.089 
 
Table 4: Outcome statistics according to patient characteristics 
 
3. Extrapolation of regional results to national situation; We calculated that our 
total eight year caseload of 23 patients, thirteen HPN patients and twelve patients with 
indications for referral to transplantation services extrapolate to 1095, 619 and 571 
respectively nationally over eight years. Ten (77%) of our HPN patients had SBS in 
comparison to the national average of 40%(18). 11/12 (92%) of our patients indicated 
for referral to transplantation services and 9/10 (90%) of patients referred had SBS, 
compared to 89/159 (55%) in the intestinal transplantation unit  (15). Our extrapolated 
annual national registration of HPN patients of 77.4 compares with 14.8 (89/6years) 
from the BANS report 2000-2005 (18) and our annual rate of referral to the intestinal 
transplantation unit of 71.4 compares to 17.3 (104/6 years)  actual referrals to the 
intestinal transplantation unit (15) (figure 1). 
 
 
 
 
DISCUSSION 
IF in the paediatric population now appears to have a better prognosis in comparison 
to adults (14;19), with a greater proportion of patients achieving complete enteral 
adaptation over time. PN and HPN are the mainstay of medical therapy whilst 
awaiting this adaptation process. Most reviewers relate increased survival to improved 
safety of delivery of PN, development of NST and earlier identification of patients 
with irreversible disease or complications such as IFALD that require referral to 
transplant services.   
 
On initial reflection our data relating to sepsis rate (1 per 40.4 patient days), severe 
IFALD (52%), and survival rate (56%) over eight years represent disappointing 
outcomes in comparison to other published work (14;15).  However, this may be 
partially attributable to variations in reporting in terms of definition of IF, and our 
local case mix. This may then have secondary effects on complications of IF 
treatment such as sepsis and development of IFALD. IF has been defined in paediatric 
                                                
 
surveys as any patient requiring PN for greater than 28 days. Other case series have 
included patients without primary intestinal disorders (including oncology and 
intensive care patients requiring PN support during prolonged courses of inpatient 
illness), or patients whom have not required PN beyond term (20). HPN is not an 
issue for these patients, and they are not candidates for CBSLT. Data gathered from 
national centres outwith the U.K. may reflect a pre-selected group that have 
demonstrated stability on PN for a period of time, and thus produces a referral bias 
which can lead to improved long-term outcomes (1;15). Other regions may also have 
patients with IF being managed beyond term by service that would not fulfil the 
criteria for NST. Our institution serves a region of 1.25 million population; it has a 
unique service organisation.  As the only centre performing neonatal surgery for the 
region, with a single NICU providing PN after term, and a single NST, we are 
confident that we have complete early ascertainment of patients with primary 
intestinal disorders who have a potential requirement for PN beyond term (as well as 
all of the older infants, children and teenagers requiring PN). These neonatal patients 
are those who are likely to require tertiary NST services, as they are the patients who 
have potential to receive HPN and/or require referral to transplant services.  
 
PN, HPN and adaptation 
We reported on over 12,000 patient days of PN with 56% of patients receiving HPN. 
Koglimeier et al (20) found that only 5% of IF patients required HPN over 2 years. 
This difference may in part be attributed to disease severity in our patients. Only 44% 
of our patients achieved enteral adaptation (not all of these patients required specialist 
NST input). Factors shown to predict time to enteral adaptation in SBS include length 
of remaining small bowel; a length of ≥40cm has been shown to a significant factor 
for earlier adaptation (10). The loss of the ICV, intestinal inflammation and bacterial 
overgrowth also appear to negatively affect adaptation (21). The primary stimulus for 
the bowel adaptation process is enteral nutrition, with early post operative feeding 
predicting shortened period of dependency on PN (22).  Other studies have reported 
marked success in weaning long-term PN patients when instituting an intestinal 
rehabilitation programme with Torres et al (23) achieving 31/37 HPN patients 
weaning successfully. This figure falls to 64% when dealing with neonatal onset 
diseases as described by Diamond et al (24). However the effects of prematurity on 
outcome are not described in either cohort. 
 
Sepsis rates and IFALD 
We report a high incidence of bacterial sepsis with a median of twelve episodes of 
sepsis per patient at a rate of one per 40.4 catheter days. Clear guidance for the use of 
long term CVC for PN delivery now exist for paediatric patients; the use of dedicated 
single lumen subclavian catheters is recommended (25). A dramatic reduction in 
bacterial sepsis rates has been shown to be associated with both non-touch sterile 
access of catheters, and having a dedicated PN nurse formally training all ward staff, 
medical staff and parents on how to access CVC (25;26) Despite  early institution of 
these measures our sepsis rate remains higher than other series, however  the 
definition of septic episodes in the literature is often unclear (27-29) and there is a 
lack of a standardised method of reporting.  
 
In our series 73% of 23 patients developed IFALD and 52% had indications for 
referral for transplant assessment. The relationship between IF, PN and cholestasis is 
not clear. Although individual constituents of PN have been shown to be hepatotoxic 
                                                
 
(11;30;31), IFALD itself has a multifactorial aetiology. Patients who are able to take 
some of their nutrition enterally appear to have partial protection from IFALD in 
comparison to patients who receive all their calories intravenously (22;32). In addition 
normal functioning small bowel would appear to protect adult populations against 
cholestasis when receiving PN (33). Recurrent bacterial sepsis has been heavily 
implicated in the development of IFALD in neonates and children (11). Colomb et al 
(34) reported a much lower rate of 23% IFALD in HPN patients, although the 
proportion of patients who were term or older children was greater in this cohort. 
Koglemeier et al (20) reported that IFALD complicated 59% of paediatric cases of IF. 
Sondheimer et al (35) reported a similar incidence of IFALD (67%) in a series of 42 
patients with SBS, and only 17% of these patients went on to develop liver failure. 
Our criteria for transplant assessment are mostly based on serum bilirubin rather than 
synthetic liver function, thus making direct comparison of results inappropriate.  52% 
of patients had indications for transplant assessment, 22% of our patients received 
organ transplantation and a further two patients died on the transplant waiting list. 
This exceeds the previously described figure of 15-20% requiring transplantation (1). 
This may partly be a reflection of the severity of disease in our cohort and also the 
relatively high incidence of bacterial sepsis predisposing to IFALD development.  In 
our series, 48% of detected organisms on blood culture were found to be either gram 
negatives or fungal, both of which are strong predictors for IFALD development (35). 
We suggest that there is a greater burden of liver disease if all IF patients in a 
geographical area are ascertained, rather than the lesser burden suggested by either 
nationally gathered data (18) or data from a single or small number of centralised 
national referral centres(14;15).   
 
Outcome 
We report only 56% survival over 8 years which is lower than other recent studies. 
Diamond et al (24) reported 62.5% over three years in an SBS cohort, Colomb et al 
(34) reported 81% survival over 10 years in a paediatric HPN cohort, and Koglemeier 
et al (20) reported 94% survival over two years in a paediatric IF series. We would, 
however, again suggest that the differences in patient ascertainment and patient mix, 
namely high rates of early referral,  prematurity and NEC (48% of our cohort had 
NEC as opposed to 24-30.8% in other paediatric IF populations (20;36)), may in part 
explain this low survival rate although numbers of patients are admittedly small. It is 
of note that of our population referred to the NST very early (<3 months of age), 
primarily because of early onset cholestasis, have a particularly poor prognosis 
(survival 33% compared to 88% if >3 months) and would have been omitted from 
other published cohorts of this condition (14). The 88% survival rate of those infants 
referred at or after 3 months of age is comparable to the survival data reported from 
large single centre HPN programmes, such as the 81% survival rate in 302 patients 
reported from Paris (34).  
 
CONCLUSIONS 
The economic impact of HPN for paediatric patients is high (37). The cost 
effectiveness of CBSLT versus long term HPN is not clear (38), and is a somewhat 
artificial argument in light of donor organ shortage for the paediatric population. 
Local factors (high incidence of NEC) may contribute to our high use of HPN. The 
registration of paediatric HPN to the BANS registry is not compulsory and therefore 
this data is likely to be incomplete. However the great excess in our series of HPN 
usage and indications for CBSLT services, compared with nationally collected data 
                                                
 
(15;18) strongly suggests that, nationally, patients may be lost due to early death, 
discontinuation of care, or non-referral, prior to reaching regional paediatric 
gastroenterology services, let alone transplantation services. Outcomes data are vital 
for service planning, but must reflect the full spectrum of the clinical arena; we 
suggest that with firmer establishment of managed clinical networks for paediatric 
nutrition support, that the patterns of care for IF patients in the UK will increasingly 
mirror the current practice in our region in terms of ascertainment and outcomes, with 
full referral of all cases of IF from early neonatal life. Such data may be of importance 
both when counselling parents and for future planning of regional IF and national 
transplant services. Our data also suggest there may be greater need for ILT and 
CBSLT assessment than currently recognised, and we suggest that the ongoing further 
national surveillance of IF may clarify the current position (BIFS study 
http://bspghan.org.uk/working_groups/nutrition.shtml).  
 
The treatment of IF in the paediatric population remains a therapeutic challenge for 
the future. These patients have highly specialised needs, best served by tertiary care 
units where sufficient surgical, medical, dietetic and nursing expertise for their 
management can be developed yet delivered closer to home. Overall throughput is 
low in terms of numbers, even in large centres. This makes randomised controlled 
trials of therapies difficult to organise in terms of feasibility. In the absence of a 
robust evidence base, standardisation of care with clinical guidelines for PN usage 
(22) together with dissemination of skills through managed clinical networks are the 
best current ways to optimise care. Close working relationships between regional 
tertiary units and the central transplant centres is of particular importance. Patient 
populations in the regional centres may differ from the experience of intestinal 
transplantation units; sharing, and honest appraisal, of patient outcomes between 
regional and intestinal transplantation centres may also help the counselling of 
parents, regional and national service planning for both HPN and intestinal transplant 
services, and long-term outcomes for these patients within the U.K.  
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What we already know on this subject: 
• The prevalence of IF is rising and long-term survival of HPN patients 
from some national centres has risen to >90% in recent years 
• IFALD contributes significantly to long term morbidity and mortality of 
these patients.  
 
 
What this study adds:  
• Outcomes from this regional data are poorer than previously described 
national data; this may reflect a fuller ascertainment and thus a greater 
burden of disease than currently recognised. 
• Regionally obtained data suggest an underestimate in national resource 
requirements for HPN and CSBLT or ILT services. 
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Figure Legend 
 
Figure 1: Comparison of RHSC Edinburgh regional data and extrapolation to 
national situation in terms of HPN registration (18) and indication for referral to 
CBSLT services) (15)expressed as patients per year.  
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